Economic evaluations of healthcare programmes and decision making: The influence of economic evaluations on different healthcare decision-making levels

PharmacoEconomics

Volumn 23, Issue 11, 2005, Pages 1075-1082

  Van Velden, Marieke E ^a   Severens, Johan L ^a,b   Novak, Annoesjka ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Roche Netherlands BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; DRUG QUALITY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH PROGRAM; LITERATURE; MEDLINE; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; REVIEW; UNITED KINGDOM;

DECISION MAKING; DELIVERY OF HEALTH CARE; EVALUATION STUDIES; HUMANS;

EID: 27744595634     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200523110-00002     Document Type: Review

References (47)

1. Hoffmann C, Graf von der Schulenberg J-M. The use of economic evaluation studies in health care decision-making: summary-report. In: Graf von der Schulenberg JM, editor. The influence of economic evaluation studies on health care decision-making. Amsterdam: IOS Press, 2000: 3-16
2. Tarn TYH, Smith MD. Pharmacoeconomic guidelines around the world. ISPOR Connections [online]. Available from URL: http://www.ispor.org/PEguidelines/ index.asp [Accessed 2004 Aug]
3. Drummond M, Dubois D, Grattini L, et al. Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value Health 1999; 2 (5): 323-32
4. Severens JL. Economic evaluation in health care: the usefulness of research guidelines. Eur J Obstet Gynecol Reprod Biol 2001 Jan; 94 (1): 5-7
5. Johannesson M. Economic evaluation of drugs and its potential uses in policy making. Pharmacoeconomics 1995; 8 (3): 190-8
6. Hoogerwerf A. Hfst. 1 Beleid, processen en effecten. In: Hoogerwerf A, Herweijer M, editors. Overheidsbeleid. Een inleiding in de beleidswetenschap. Samsom: Alphen aan den Rijn, 1998: 17-35
7. Weiss CH. Chapter 3: The haphazard connection: social science and public policy. Int J Educ Res 1995; 23 (2): 137-50
8. Dunn WN. Public policy analysis: an introduction. Upper Saddle River (NJ): Pearson Prentice Hall, 2004
9. Anell A, Svarvar P. Pharmacoeconomics and clinical practice guidelines: a survey of attitudes in Swedish formulary committees. Pharmacoeconomics 2000 Feb; 17 (2): 175-85
10. Bloom BS. Use of formal benefit/cost evaluations in health system decision making. Am J Manag Care 2004 May; 10 (5): 329-35
11. Drummond M, Cooke J, Walley T. Economic evaluation under managed competition: evidence from the UK. Soc Sci Med 1997 Aug; 45 (4): 583-95
12. Duthie T, Trueman P, Chancellor J, et al. Research into the use of health economics in decision making in the United Kingdom: phase II. Is health economics 'for good or evil'? Health Policy 1999 Jan; 46 (2): 143-57
13. Hoffmann C, Stoykova BA, Nixon J, et al. Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. Value Health 2002; 5 (2): 71-9
14. Luce BR, Brown RE. The use of technology assessment by hospitals, health maintenance organizations, and third-party payers in the United States. Int J Technol Assess Health Care 1995; 11 (1): 79-92
15. Martin DK, Pater JL, Singer PA. Priority-setting decisions for new cancer drugs: a qualitative case study. Lancet 2001 Nov 17; 358 (9294): 1676-81
16. Nuijten MJC, et al. Health care reform in six Central European countries. Eur J Health Econ 2003 Dec; 4 (4): 286-91
17. PausJenssen AM, Singer PA, Detsky AS. Ontario's formulary committee: how recommendations are made. Pharmacoeconomics 2003; 21 (4): 285-94
18. Ross J, The use of economic evaluation in health care: Australian decision makers' perceptions. Health Policy 1995 Feb; 31 (2): 103-10
19. Singer PA, Martin DK, Giacomini M, et al. Priority setting for new technologies in medicine: qualitative case study. BMJ 2000 Nov; 321 (7272): 1316-8
20. Steiner CA, Powe NR, Anderson GF, et al. Technology coverage decisions by health care plans and considerations by medical directors. Med Care 1997 May; 35 (5): 472-89
21. Walley T, Barton S, Cooke J, et al. Economic evaluations of drug therapy: attitudes of primary care prescribing advisors in Great Britain. Health Policy 1997 Jul; 41 (1): 61-72
22. Weatherly H, Drummond M, Smith D. Using evidence in the development of local health policies: some evidence from the United Kingdom. Int J Technol Assess Health Care 2002; 18 (4): 771-81
23. West R, Borden EK, Collet JP, et al. "Cost-effectiveness" estimates results in flawed decision-making in listing drugs for reimbursement. Can J Public Health 2002 Nov-Dec; 93 (6): 421-5
24. Zwart-van Rijkom JE, Leufkens HG, Busschbach JJ, et al. Differences in attitudes, knowledge and use of economic evaluations in decision-making in the Netherlands: the Dutch results from the EUROMET Project. Pharmacoeconomics 2000 Aug; 18 (2): 149-60
25. Cox E, Motheral B, Griffis D. ISPOR Fifth Annual International Meeting Contributed Presentation Abstracts: relevance of pharmacoeconomics and health outcomes information to health care decision-makers in the United States (PDH23) [abstract]. Value Health 2000; 3 (2): 162
26. Evans C, Dukes EM, Crawford B. The role of pharmacoeconomic information in the formulary decision-making process. J Manag Care Pharm 2000 Mar-Apr; 6 (2): 108, 113-4, 117-8, 121
27. Grabowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med 1997 Aug; 45 (4): 535-44
28. Grizzle AJ, Motheral B, Garrity B, et al. ISPOR Fifth Annual International Meeting Contributed Presentation Abstracts: a qualitative assessment of managed care decision-maker's views and use of pharmacoeconomic information (PDH25). Value Health 2000; 3 (2): 162-3
29. Grizzle AJ, Olson BM, Motheral BR, et al. Therapeutic value? Who decides? Pharmaceutical Executive 2000 Nov; 20 (11): 84-90
30. Jenkings KN, Barber N. What constitutes evidence in hospital new drug decision making? Soc Sci Med 2004 May; 58 (9): 1757-66
31. Luce BR, Lyles CA, Rentz AM. The view from managed care pharmacy. Health Aff 1996 Winter; 15 (4): 168-76
32. Lyles A, Luce BR, Rentz AM. Managed care pharmacy, socio-economic assessments and drug adoption decisions. Soc Sci Med 1997 Aug; 45 (4): 511-21
33. Martin DK, et al. Priority setting in a hospital drug formulary: a qualitative case study and evaluation. Health Policy 2003 Dec; 66 (3): 295-303
34. Martin DK, Hollenberg D, MacRae S, et al. Role of pharmacoeconomics in drug benefit decision-making: results of a survey. Formulary 2000 May; 35: 412-21
35. Odedina FT, Sullivan J, Nash R, et al. Use of pharmacoeconomic data in making hospital formulary decisions. Am J Health Syst Pharm 2002 Aug; 59 (15): 1441-4
36. Sloan FA, Whetten-Goldstein K, Wilson A. Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis. Soc Sci Med 1997 Aug; 45 (4): 523-33
37. Spath HM, Charavel M, Morelle M, et al. A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey. Pharm World Sci 2003 Dec; 25 (6): 269-75
38. Steiner CA, Powe NR, Anderson GF, et al. The review process used by US health care plans to evaluate new medical technology for coverage. J Gen Intern Med 1996 May; 11 (5): 294-302
39. Brody B, Wray N, Bame S, et al. The impact of economic considerations on clinical decision-making: the case of thrombolytic therapy. Med Care 1991 Sep; 29 (9): 899-910
40. Erkan D, Yazici Y, Harrison MJ, et al. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy. Arthritis Rheum 2002 Jun 15; 47 (3): 285-90
41. Ginsberg ME, Kravitz RL, Sandberg WA. A survey of physician attitudes and practices concerning cost-effectiveness in patient care. West J Med 2000 Dec; 173 (6): 390-4
42. Kangis P, Van der Geer L. Pharmaco-economic information and its effect on prescriptions. J Manag Med 1996; 10 (5): 66-74
43. Ubel PA, Jepson C, Baron J, et al. The influence of cost-effectiveness information on physicians' cancer screening recommendations. Soc Sci Med 2003 Apr; 56 (8): 1727-36
44. Wu O, Knill-Jones R, Wilson P, et al. The impact of economic information on medical decision making in primary care. J Eval Clin Pract 2004 Aug; 10 (3): 407-11
45. Suh DC, Okpara IR, Agnese WB, et al. Application of pharmacoeconomics to formulary decision making in managed care organizations. Am J Manag Care 2002; 8 (2): 161-9
46. Ubel P. Physicians' duties in an era of cost containment: advocacy or betrayal? [letter]. JAMA 1999 Nov; 282 (17): 1675
47. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-52